AcquisitionOther

MAXCYTE, INC. acquired Akron Bio,

Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.

Deal tape row

MAXCYTE, INC. -> Akron Bio, · $34.5 million

I believe combining MaxCyte and Akron will expand our commercial opportunity, strengthen our financial profile, and drive long-term value," said Maher Masoud, President and CEO of MaxCyte.

Open source record (SEC) ↗

Have a question, or want to talk something through?

Let's Talk